Drugs / EG1206A
EG1206A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05471648 | May 2022 → Jan 2023 | breast cancer | EirGenix, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06884254 | May 2025 → Nov 2026 | breast cancer | EirGenix, Inc. | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | EirGenix, Inc. | Regulatory EirGenix Inc. Achieves Major Milestone: Breast Cancer Biosimilar Candidate -EG1206A Receives Favorable Response Regarding Phase III Clinical Trial Waiver eirgenix.com ↗
Consequently, the company has officially terminated the on-going Phase III clinical trial for EG1206A. |
| 2023-05-01 | EirGenix, Inc. | Results EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives eirgenix.com ↗
Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show that the main test indicators have met the pharmacokinetics bioequivalence standard. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG1206A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06884254 ↗ |
| Known as | EirGenix Pertuzumab | “420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection” NCT05471648 ↗ |
| Known as | Pertuzumab | “Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.” NCT06884254 ↗ |
| Route | Intravenous | “EirGenix Pertuzumab given intravenous with an infusion bag as a single dose of 420 mg over 60min.” NCT05471648 ↗ |